Company Description
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia.
The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues.
Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens.
The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021.
The company was founded in 2003 and is based in Hamilton, Bermuda.
| Country | Bermuda |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Dr. Thomas Meyer Ph.D. |
Contact Details
Address: Clarendon House, 2 Church Street Hamilton Hm 11, D0 00000 Bermuda | |
| Phone | 41 (0) 41 729 71 94 |
| Website | altamiratherapeutics.com |
Stock Details
| Ticker Symbol | CYTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001601936 |
| CUSIP Number | G0360L100 |
| ISIN Number | BMG0360L1349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, President, Chairman, Chief Executive Officer and MD |
| Marcel Gremaud C.P.A. | Chief Financial Officer |
| Dr. Covadonga Paneda | Chief Operating Officer |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Adviser |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 10, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Apr 10, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 22, 2024 | 424B4 | Prospectus |
| Jan 19, 2024 | EFFECT | Notice of Effectiveness |
| Jan 19, 2024 | 6-K | Report of foreign issuer |
| Jan 19, 2024 | 424B5 | Filing |
| Jan 19, 2024 | 6-K | Report of foreign issuer |